Cargando…

Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance

Acquired chemotherapeutic resistance of cancer cells can result from a Darwinistic evolution process in which heterogeneity plays an important role. In order to understand the impact of genetic heterogeneity on acquired resistance and second line therapy selection in metastatic melanoma, we sequence...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raaijmakers, Marieke I. G., Widmer, Daniel S., Narechania, Apurva, Eichhoff, Ossia, Freiberger, Sandra N., Wenzina, Judith, Cheng, Phil F., Mihic-Probst, Daniela, Desalle, Rob, Dummer, Reinhard, Levesque, Mitchell P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363577/ https://www.ncbi.nlm.nih.gov/pubmed/27791198 http://dx.doi.org/10.18632/oncotarget.12848

Ejemplares similares

Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma
por: Cheng, Phil F, et al.
Publicado: (2015)

A DNA replication-independent function of pre-replication complex genes during cell invasion in C. elegans
por: Lattmann, Evelyn, et al.
Publicado: (2022)

Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases
por: Zila, Nina, et al.
Publicado: (2018)

Analysis of adenovirus trans-complementation-mediated gene expression controlled by melanoma-specific TETP promoter in vitro
por: Fontecedro, Alessandra Curioni, et al.
Publicado: (2010)

Targeted treatment of advanced NRAS-mutated melanoma
por: Koelblinger, Peter, et al.
Publicado: (2017)

Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques
por: Schoenewolf, Nicola L., et al.
Publicado: (2012)

Atypical BRAF and NRAS Mutations in Mucosal Melanoma
por: Dumaz, Nicolas, et al.
Publicado: (2019)

Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?
por: Mangana, Joanna, et al.
Publicado: (2015)

Phase I, open-label study of pasireotide in patients with BRAF-wild type and NRAS-wild type, unresectable and/or metastatic melanoma
por: Dummer, Reinhard, et al.
Publicado: (2018)

BRAF, NRAS, and GNAQ Mutations in Conjunctival Melanocytic Nevi
por: Francis, Jasmine H., et al.
Publicado: (2018)

Insect Phylogenomics: Exploring the Source of Incongruence Using New Transcriptomic Data
por: Simon, Sabrina, et al.
Publicado: (2012)

NRAS and BRAF Mutations in Melanoma-Associated Nevi and Uninvolved Nevi
por: Tschandl, Philipp, et al.
Publicado: (2013)

BRAF and NRAS Mutations are Heterogeneous and Not Mutually Exclusive in Nodular Melanoma
por: Chiappetta, Caterina, et al.
Publicado: (2015)

Frequent Occurrence of NRAS and BRAF Mutations in Human Acral Naevi
por: Jansen, Philipp, et al.
Publicado: (2019)

KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma
por: Pasca, Sergiu, et al.
Publicado: (2019)

Seriniquinones as Therapeutic Leads for Treatment of BRAF and NRAS Mutant Melanomas
por: Hirata, Amanda S., et al.
Publicado: (2021)

Morphological Characters Can Strongly Influence Early Animal Relationships Inferred from Phylogenomic Data Sets
por: Neumann, Johannes S, et al.
Publicado: (2020)

UVB mutagenesis differs in Nras- and Braf-mutant mouse models of melanoma
por: Bowman, Robert L, et al.
Publicado: (2021)

Enhanced BRAF engagement by NRAS mutants capable of promoting melanoma initiation
por: Murphy, Brandon M., et al.
Publicado: (2022)

Long‐Term Response to Intermittent Binimetinib in Patients with NRAS‐Mutant Melanoma
por: Matter, Alexandra Valeska, et al.
Publicado: (2020)

Coexpression of SOX10/CD271 (p75(NTR)) and β-Galactosidase in Large to Giant Congenital Melanocytic Nevi of Pediatric Patients
por: Barysch, Marjam J., et al.
Publicado: (2014)

P38 Mediates Tumor Suppression through Reduced Autophagy and Actin Cytoskeleton Changes in NRAS-Mutant Melanoma
por: Banik, Ishani, et al.
Publicado: (2023)

Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma
por: Colombino, Maria, et al.
Publicado: (2013)

BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib
por: Ranzani, Marco, et al.
Publicado: (2015)

Prevalence of BRAF, NRAS and c-KIT Mutations in Slovenian Patients with Advanced Melanoma
por: Moltara, Maja Ebert, et al.
Publicado: (2018)

Many Distinct Ways Lead to Drug Resistance in BRAF- and NRAS-Mutated Melanomas
por: Vachtenheim, Jiri, et al.
Publicado: (2021)

Intra-patient Heterogeneity of BRAF and NRAS Molecular Alterations in Primary Melanoma and Metastases
por: PELLEGRINI, Cristina, et al.
Publicado: (2020)

Imaging Mass Spectrometry for the Classification of Melanoma Based on BRAF/NRAS Mutational Status
por: Casadonte, Rita, et al.
Publicado: (2023)

Molecular Pattern and Clinical Implications of KRAS/NRAS and BRAF Mutations in Colorectal Cancer
por: Gökmen, İvo, et al.
Publicado: (2023)

Specific Activation of the CD271 Intracellular Domain in Combination with Chemotherapy or Targeted Therapy Inhibits Melanoma Progression
por: Saltari, Annalisa, et al.
Publicado: (2021)

Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors
por: Jaiswal, Bijay S., et al.
Publicado: (2009)

BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases
por: Fakhruddin, Najla, et al.
Publicado: (2017)

An Aggressive Hypoxia Related Subpopulation of Melanoma Cells is TRP-2 Negative()()
por: Lenggenhager, Daniela, et al.
Publicado: (2014)

Who’s Driving? Switch of Drivers in Immunotherapy-Treated Progressing Sinonasal Melanoma
por: Freiberger, Sandra N., et al.
Publicado: (2021)

Development of encorafenib for BRAF-mutated advanced melanoma
por: Koelblinger, Peter, et al.
Publicado: (2018)

KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases
por: Zebary, A, et al.
Publicado: (2013)

Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients
por: Hsu, Hung-Chih, et al.
Publicado: (2016)

KRAS, NRAS, and BRAF mutations in plasma cell myeloma at a single Korean institute
por: Kim, Yonggoo, et al.
Publicado: (2020)

Mutations in the BRAF, NRAS, and C-KIT Genes of Patients Diagnosed with Melanoma in Colombia Population
por: Gutiérrez-Castañeda, Luz D., et al.
Publicado: (2020)

KRAS/NRAS/BRAF Mutation Rate in Saudi Academic Hospital Patients With Colorectal Cancer
por: Saharti, Samah
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qsvg0kp9vghbtsm27uhpoqd42a